Elanco Animal Health (ELAN) EBITDA (2017 - 2026)

Elanco Animal Health has disclosed EBITDA across 10 years of filings, most recently posting $248.0 million for Q2 2026.

• In Q2 2026, EBITDA rose 12.73% year-over-year to $248.0 million; the TTM figure through Jun 2026 stood at $637.0 million (up 2648.0% YoY), while the FY2025 annual figure was $558.0 million, up 136.83% from the prior year.
• EBITDA came in at $248.0 million for Q2 2026 at Elanco Animal Health, down from $291.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $291.0 million in Q1 2026 to a low of -$1.6 billion in Q3 2023.
• Average EBITDA over 5 years is -$307.2 million, with a median of -$466.0 million recorded in 2022.
• Year-over-year, EBITDA sank 206.98% in 2023 and soared 147.71% in 2025.
• Over 5 years, EBITDA stood at -$537.0 million in 2022, then slipped by 19.74% to -$643.0 million in 2023, then increased by 14.15% to -$552.0 million in 2024, then jumped by 92.03% to -$44.0 million in 2025, then jumped by 663.64% to $248.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $248.0 million in Q2 2026, $291.0 million in Q1 2026, and -$44.0 million in Q4 2025.